Court Opinion

ID: 4220231
Source: CourtListenerOpinion
Date Created: 2017-11-14 17:02:08.605871+00
Date Added: 2024-06-11T14:15:22.961713
License: Public Domain

In the United States Court of Federal Claims
                                     OFFICE OF SPECIAL MASTERS
                                              No. 14-191V
                                          (Not to be Published)

*****************************
KYLE CARDA and SHANNON CARDA, on *
behalf of G.J.C.,                *                                        Special Master Corcoran
                                 *
                  Petitioners,   *                                        Filed: September 5, 2017
                                 *
               v.                *                                        Decision; Attorney’s Fees and Costs.
                                 *                                        Interim Request
                                 *
SECRETARY OF HEALTH AND          *
HUMAN SERVICES,                  *
                                 *
                  Respondent.    *
                                 *
*****************************

Robert D. Trzynka, Cutler & Donahoe, LLP, Sioux Falls, SD, for Petitioners.

Sarah C. Duncan, U. S. Dep’t of Justice, Washington, DC, for Respondent.

    DECISION DENYING MOTION FOR INTERIM ATTORNEY’S FEES AND COSTS1

        On March 6, 2014, Kyle and Shannon Carda filed a petition on behalf of their minor child,
G.J.C., seeking compensation under the National Vaccine Injury Compensation Program.2
Petitioners allege that G.J.C. experienced an intussusception as a result of receiving the Rotateq
rotavirus vaccine on January 23, 2013, and March 26, 2013. ECF No. 1. The matter was tried on
January 24-25, 2017, and a decision is pending.

1
  Although this decision has not been designated for publication, it will nevertheless be posted on the United States
Court of Federal Claims’ website, and in accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 (2012).
This means the ruling will be available to anyone with access to the internet. As provided by 42 U.S.C. § 300aa-
12(d)(4)(B), however, the parties may object to the published ruling’s inclusion of certain kinds of confidential
information. Specifically, under Vaccine Rule 18(b), each party has fourteen (14) days within which to request
redaction “of any information furnished by that party: (1) that is a trade secret or commercial or financial in substance
and is privileged or confidential; or (2) that includes medical files or similar files, the disclosure of which would
constitute a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). Otherwise, the entire decision will be
available in its current form. Id.
2
 The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660,
100 Stat. 3758, codified as amended at 42 U.S.C. §§ 300aa-10 through 34 (2012) (“Vaccine Act” or “the Act”).
        Petitioners have asked for an interim award of fees and costs on two occasions. On July 7,
2016, Petitioners filed their first such request, seeking an interim award of $54,870.21 in total. See
First Motion for Interim Attorney’s Fees and Expenses, dated July 7, 2016 (ECF No. 40). I granted
this motion in part, awarding interim fees and costs of $34,122.83. See Decision, dated August 19,
2016 (ECF No. 45) (“First Interim Attorney’s Fees Decision”). Although I awarded most of the
fees requested, I granted only half of the requested expert costs, on the grounds that they were
insufficiently justified or premature, but indicated that Petitioners could request the remainder of
that expert time after hearing. See First Interim Fees Decision at 6.

         After the hearing, Petitioners filed a second interim motion for attorney’s fees and costs on
February 16, 2017. ECF No. 80. That motion sought reimbursement of attorney’s fees and costs
in the amount of $75,798.45 – representing $29,244.90 in additional attorney’s fees; $14,588.47
in attorney’s costs; and $31,964.98 in past unreimbursed and current expert costs – and reflecting
work performed between July 2016 and the January 2017 hearing. By decision dated March 23,
2017, I granted the second fees and costs request in part, allowing an award of approximately
$24,000.00 to reimburse Petitioners for their experts’ testimony, plus a sum awarded for the Cardas
personal travel costs to appear at the hearing. ECF No. 82 (“Second Fees Dec.”). I deferred
resolution of Petitioners’ attorney’s fees request, however, noting that I had already made one such
award, and that therefore the grounds for a second interim award were far less persuasive. Second
Fees Dec. at 3-4. I also stated that additional attorney’s fees might be generated in the case, and
that it would be preferable to defer action on the request until the case was truly over. Id. at 4.

         Despite my prior determination (and accompanying disclosure of my views on the
propriety of multiple interim fees awards in a Vaccine Program case), Petitioners have now made
a third interim request. See Motion, dated August 22, 2017 (ECF No. 91) (“Third Fees Req.”). In
it, they request $76,482.98 in attorney’s fees for work completed between July 2016 and June 2017
(and thus incorporating the fees I previously refused to award on an interim basis), arguing that
some of Petitioners’ fees are now over a year old and should be accounted for before the end of
2017. Further, Petitioners argue that the entitlement hearing and post-trial brief required a
substantial amount of research. Third Fees Req. at 2-3. The present motion does not include any
cost request.3

       The new fees motion, however, establishes no special circumstances justifying yet another
fees award. See Avera v. Sec’y of Health & Human Servs., 515 F.3d 1343, 1350 (Fed. Cir. 2008)

3
  Respondent filed a brief reacting to Petitioners’ fee request on September 5, 2017. ECF No. 93. Respondent defers
to my determination of whether or not Petitioners have met the legal standards for an award of interim fees and costs,
but is otherwise satisfied that the statutory requirements for an award of attorney’s fees and costs has been met. Id. at
2.

                                                           2
(limiting interim fees to cases where proceedings are protracted and costly experts must be
retained); King v. Sec’y of Health & Human Servs., No. 03-584V, 2009 WL 2252534, at *3-4 (Fed.
Cl. Spec. Mstr. July 10, 2009). Nor does it directly address my prior points about my preference
to limit the number of interim awards in a given case. See Carda v. Sec’y of Health & Human
Servs., No. 14-191V, 2017 WL 1709707, at *2 (Fed. Cl. Spec. Mstr. Mar. 23, 2017). With two
such awards already issued, that limit has been reached, and (in my discretion to award any interim
fee), I see no basis for yet another.

        I am sympathetic to counsel’s desire to be compensated for work on this case as soon as
possible. But the Vaccine Program is not a lawyers’ aid society. Rather, it exists to aid claimants
- and their counsel only indirectly. The Program’s policy goal of encouraging competent counsel
to appear for claimants is served by its generous fees provisions, but is not subverted by requiring
counsel in appropriate circumstances to await a fees award until the case is over.

        Accordingly, and for the reasons stated, I DENY Petitioners’ third interim fees request.
Petitioners may file a final fees request at the close of the case, and may include in that request
any fees not awarded to date but incurred in work on this matter.

       IT IS SO ORDERED.
                                                          /s/ Brian H. Corcoran
                                                             Brian H. Corcoran
                                                             Special Master

                                                 3